Breast carcinoma in women over the age of 85: Distinct histological pattern and androgen, oestrogen, and progesterone receptor status

Histopathology

Volumn 42, Issue 2, 2003, Pages 120-127

  Honma, Naoko ^a,f   Sakamoto, G ^a   Akiyama, F ^a   Esaki, Y ^a,b   Sawabe, M ^c   Arai, T ^c   Hosoi, T ^c   Harada, N ^d   Younes, M ^e   Takubo, K ^a  

^a CANCER INSTITUTE   (Japan)

^b Sekishinkai Sayama Hospital   (Japan)

^c Tokyo Metropolitan Institute of Gerontology   (Japan)

^d FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

Author keywords

Androgen receptor; Apocrine carcinoma; Breast carcinoma; Elderly; GCDFP 15; Mucinous carcinoma; Oestrogen receptor ; Oestrogen receptor ; Progesterone receptor

Indexed keywords

ANDROGEN RECEPTOR; CELL PROTEIN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GROSS CYSTIC DISEASE FLUID PROTEIN 15; PROGESTERONE RECEPTOR; STEROID RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANDROGEN BLOOD LEVEL; APOCRINE CARCINOMA; ARTICLE; BREAST CARCINOMA; CLINICAL ARTICLE; ELDERLY CARE; ESTROGEN BLOOD LEVEL; FEMALE; HISTOPATHOLOGY; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; MOLECULAR INTERACTION; MOLECULAR MECHANICS; MUCINOUS CARCINOMA; PATHOGENESIS; PREMENOPAUSE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROTEIN EXPRESSION; RECEPTOR DENSITY; STATISTICAL SIGNIFICANCE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; PREMENOPAUSE; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 12244257781     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.2003.01542.x     Document Type: Article

References (34)

1. Rosen PP, Lesser ML, Kinne DW. Breast carcinoma at the extremes of age: a comparison of patients younger than 35 years and older than 75 years. J. Surg. Oncol. 1985; 28; 90-96.
2. Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J. Natl. Cancer Inst. 2000; 92; 550-556.
3. Davis SJ, Karrer FW, Moor BJ, Rose SG, Eakins G. Characteristics of breast cancer in women over 80 years of age. Am. J. Surg. 1985; 150; 655-658.
4. Toikkanen S, Kujari H. Pure and mixed mucinous carcinomas of the breast: a clinicopathologic analysis of 61 cases with long-term follow-up. Hum. Pathol. 1989; 20; 758-764.
5. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896; ii; 104-107.
6. Eskin BA. The menopause: comprehensive management. New York: McGraw-Hill, 1994; 8.
7. Busch E, Kemeny M, Fremgen A, Osteen RT, Winchester DP, Clive RE. Patterns of breast cancer care in the elderly. Cancer 1996; 78; 101-111.
8. Pujol P, Daures JP, Thezenas S, Guilleux F, Rouanet P, Grenier J. Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause. Cancer 1998; 83; 698-705.
9. Collett K, Hartveit F, Skjærven R, Mæhle BO. Prognostic role of oestrogen and progesterone receptors in patients with breast cancer: relation to age and lymph node status. J. Clin. Pathol. 1996; 49; 920-925.
10. Fernö M. Borg Å, Johansson U et al. Estrogen and progesterone receptor analyses in more than 4000 human breast cancer samples. Acta Oncol. 1990; 29; 129-135.
11. Thorpe SM. Estrogen and progesterone receptor determinations in breast cancer. Technology, biology and clinical significance. Acta Oncol. 1988; 27; 1-19.
12. World Health Organization. Histological typing of breast tumours. 2nd edn. International Histological Classification of Tumours no. 2. Geneva: World Health Organization. 1981.
13. Mazoujian G, Pinkus GS, Davis S, Haagensen DE Jr. Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast. A marker of apocrine epithelium and breast carcinomas with apocrine feature. Am. J. Pathol. 1983; 110; 105-112.
14. Mann S, Laucirica R, Carlson N et al. Estrogen receptor beta expression in invasive breast cancer. Hum. Pathol. 2001; 32; 113-118.
15. Eusebi V, Betts C, Haagensen DE Jr, Gugliotta P, Bussolati G, Azzopardi JG. Apocrine differentiation in lobular carcinoma of the breast: a morphologic, immunologic, and ultrastructural study. Hum. Pathol. 1984; 15; 134-140.
16. Walford N, ten Velden J. Histiocytoid breast carcinoma: an apocrine variant of lobular carcinoma. Histopathology 1989; 14; 515-522.
17. Koenig C, Tavassoli FA. Mucinous cystadenocarcinoma of the breast. Am. J. Surg. Pathol. 1998; 22; 698-703.
18. Takubo K. Mastopathy of the elderly. In Sakamoto G ed. Clinicopathology of mastopathy (in Japanese). Tokyo: Shinohara Press, 1997: 37-43.
19. Mossler JA, Barton TK, Brinkhous AD, McCarty KS, Moylan JA, McCarty KS Jr. Apocrine differentiation in human mammary carcinoma. Cancer 1980; 46; 2463-2471.
20. d'Amore ESG, Terrier-Lacombe MJ, Travagli JP, Friedman S, Contesso G. Invasive apocrine carcinoma of the breast: a long-term follow-up study of 34 cases. Breast Cancer Res. Treat. 1988; 12; 37-44.
21. Frable WJ, Kay S. Carcinoma of the breast. Histologic and clinical features of apocrine tumors. Cancer 1968; 21; 756-763.
22. Sakamoto G. Sugano H. Pathology of breast cancer: present and prospect in Japan, Breast Cancer Res. Treat. 1991; 18; S81-S83.
23. Miller WR, Telford J, Dixon JM, Shivas AA. Androgen metabolism and apocrine differentiation in human breast cancer. Breast Cancer Res. Treat. 1985; 5; 67-73.
24. Tavassoli FA, Purcell CA, Bratthauer GL, Man YG. Androgen receptor expression along with loss of bcl-2, ER, and PR expression in benign and malignant apocrine lesions of the breast: implications for therapy. Breast J. 1996; 2; 261-269.
25. Bulbrook RD, Hayward JL, Spicer CC. Relation between urinary androgen and corticoid excretion and subsequent breast cancer. Lancet 1971; 2; 395-398.
26. Hackenberg R, Luttchens S, Hofmann J, Kunzmann R, Hozel F, Schulz KD. Androgen sensitivity of the new human breast cancer cell line MFM-223. Cancer Res. 1991; 51; 5722-5727.
27. Hackenberg R, Hofmann J, Holzel F, Schulz KD. Stimulatory effects of androgen and antiandrogen on the in vitro proliferation of human mammary carcinoma cells. J. Cancer Res. Clin. Oncol. 1988; 114; 593-601.
28. Berrino F, Muti P, Micheli A et al. Serum sex hormone levels after menopause and subsequent breast cancer. J. Natl. Cancer Inst. 1996; 88; 291-296.
29. Dorgan JF, Longcope C, Stephenson HE Jr, et al. Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk. Cancer Epidemiol. Biomarkers Prey. 1996; 5; 533-539.
30. Birrell SN, Roder DM, Horsfall DJ, Bentel JM, Tilley WD. Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression. J. Clin. Oncol. 1995; 13; 1572-1577.
31. Isola JJ. Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J. Pathol. 1993; 170; 31-35.
32. Kuenen-Boumeester V, Van der Kwast ThH, Van Putten WLJ, Claassen C, Van Ooijen B, Henzen-Logmans SC. Immunohistochemical determination of androgen receptors in relation to oestrogen and progesterone receptors in female breast cancer. Int. J. Cancer 1992; 52; 581-584.
33. Savouret JF, Bailly A, Misrahi M et al. Characterization of the hormone responsive element involved in the regulation of the progesterone receptor gene. EMBO J. 1991; 10; 1875-1883.
34. Pink JJ, Jordan VC. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res. 1996; 56; 2321-2330.